We’re developing an elegant solution for masking small molecules, with conditional activation across all solid tumors.

Our proprietary tumor selective Alnair Nanoparticle (ALN) platform makes trusted drugs safer and more efficacious via Dose Intensification!

Our Unfair Advantage

The first nanoparticle platform to enable true lactate-responsive drug release

not pH, hypoxia, or other metabolites

Sustained ultra-high lactate levels are a universal metabolite across all solid tumors and the gap is the target

Tumors rely on aerobic glycolysis where they consume large amounts of glucose and convert it directly into lactate, even when oxygen is available. This process fuels rapid cell division and results in a high concentration of lactate being secreted, which becomes even higher in aggressive tumors.

The lactate concentration represented for "healthy tissues" is the max lactate found in tissues under healthy metabolic states.

Selective Release Inside the TME

The Alnair Lactate-reactive Nanoparticle (ALN) is composed of a Mesoporous Silica Nanoparticle (MSN) packed with a benefit agent covered by our proprietary lactate-reactive cap. The ALN is then capable of selectively releasing the benefit agent in the lactate-rich Tumor Micro Environment (TME). While many companies have failed to target the Warburg Effect via surrogate biomarkers, like pH-sensitive linkers, Alnair has become the first company to successfully target lactate itself.

In the Weeds: Tunable Smart Cap

We have engineered a lactate-reactive “cap” that is self-immolative in the presence of lactate. The ALN cap is composed of a peroxide-sensitive linker binding the surface of the MSN to cyclodextrin, which in turn is functionalized with an enzyme that oxidizes lactate. This is a tunable system that allows for changes in lactate sensitivity.

Rapidly Scalable Pipeline

Turning trusted first line cancer therapies into transformative precision-targeted treatments via rapid prototyping.

We are de-risking the ALN platform by reducing chemotherapy-related cardiotoxicity while expanding its therapeutic window via dose intensification.

In parallel, we aim to enable new treatment types (i.e. immunomodulatory agents) and help companies revive dead assets by bringing our safety profile to any API.

  • Indication: Breast, Ovarian, Sarcoma

    Stage: Lead program, advancing to IND

  • Indication: Breast, Colorectal,

    Stage: Target identification completed

  • Indication: Polydinamic therapy

    Existing Market: Niche

    Stage: Novel exploration, loaded

Partners

Contact us.

400 N Aberdeen St, 9th Floor, Chicago, IL 60642
Chicago, IL 60642

RECRUITMENT FRAUD ALERT: Be aware of scammers impersonating Alnair Therapeutics recruiters using personal email domains (e.g., @comcast.net, @gmail.com, or @alnairbio.info). Alnair only communicates via official @alnairbio.com email addresses. We will never ask for money or sensitive financial details during the hiring process.